MedPath

Galactose

Generic Name
Galactose
Drug Type
Small Molecule
Chemical Formula
C6H12O6
CAS Number
59-23-4
Unique Ingredient Identifier
X2RN3Q8DNE
Background

Galactose has been used in trials studying the treatment and diagnosis of Hepatitis C, Hepatic Cancer, Wilsons Disease, Diabetic Macular Oedema, and Focal Segmental Glomerulosclerosis, among others. There are even proposals for its use in accelerating senescence in mice, rats, and Drosophila, for its association with ovarian cancer, or even for the potential treatment of focal segmental glomerulosclerosis. Nevertheless, none of these ongoing studies have yet provided formal elucidation for their proposals.

As a naturally occurring sugar, it may be found in a number dairy products. Even then, however, it is not generally used as a sweetener considering it is only about 30% as sweet as sucrose. Regardless, although it is predominantly used as a pathway to generate glucose fuel for the human body, galactose is involved as an ingredient in some commonly used vaccines and non-prescription products.

Indication

There are limited therapeutic uses for which galactose is formally indicated. Some predominant indications include (a) the use of galactose to facilitate the construction of structurally and immunologically effective attenuated vaccines , and (b) the role galactose plays as an essential element in the formation of lactulose - a synthetic disaccharide indicated for the treatment of constipation and/or hepatic encephalopathy (HE); hepatic coma .

Nevertheless, there are many studies looking into a variety of possible uses for galactose, including the use of the monosaccharide sugar for accelerating senescence in mice, rats, and Drosophila , the proposed association between galactose in consumed milk and ovarian cancer , a possible role in the therapy of focal segmental glomerulosclerosis , among various others. Regardless, none of these proposed indications have yet been formally elucidated for practical use.

Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)

Phase 2
Not yet recruiting
Conditions
PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation
Interventions
Drug: Placebo
First Posted Date
2022-06-02
Last Posted Date
2025-03-25
Lead Sponsor
Eva Morava-Kozicz
Target Recruit Count
8
Registration Number
NCT05402332
Locations
πŸ‡ΊπŸ‡Έ

Mayo Clinic Rochester, Rochester, Minnesota, United States

AVTX-801 D-galactose Supplementation in SLC35A2-CDG

Phase 2
Not yet recruiting
Conditions
SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
Interventions
Drug: Placebo
First Posted Date
2022-06-02
Last Posted Date
2024-10-24
Lead Sponsor
Eva Morava-Kozicz
Target Recruit Count
10
Registration Number
NCT05402384
Locations
πŸ‡ΊπŸ‡Έ

Mayo Clinic Minnesota, Rochester, Minnesota, United States

sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

Not Applicable
Completed
Conditions
Wilsons Disease
Interventions
Procedure: Fibroscan
Procedure: Ultrasound
Procedure: Liver biopsy
Procedure: Functional hepatic nitrogen clearance
First Posted Date
2016-03-09
Last Posted Date
2022-11-02
Lead Sponsor
University of Aarhus
Target Recruit Count
33
Registration Number
NCT02702765
Locations
πŸ‡©πŸ‡°

Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C

Completed
Conditions
Hepatitis C
Interventions
Procedure: Gastroscopy
Procedure: Liver biopsy
Procedure: Fibroscan
Procedure: Liver vein catheterization
First Posted Date
2015-08-19
Last Posted Date
2020-04-07
Lead Sponsor
University of Aarhus
Target Recruit Count
71
Registration Number
NCT02528461
Locations
πŸ‡©πŸ‡°

Aarhus University Hospital, Aarhus C, Denmark

Direct Peritoneal Resuscitation Plus Conventional Resuscitation

Phase 4
Withdrawn
Conditions
Hepatic Cancer
Interventions
Drug: Standard Treatment
First Posted Date
2013-06-20
Last Posted Date
2017-05-05
Lead Sponsor
University of Louisville
Registration Number
NCT01882218
Locations
πŸ‡ΊπŸ‡Έ

University of Louisville Hospital, Louisville, Kentucky, United States

πŸ‡ΊπŸ‡Έ

Norton Hospital, Louisville, Kentucky, United States

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

Not Applicable
Completed
Conditions
Focal Segmental Glomerulosclerosis
Steroid Resistant Nephrotic Syndrome
Interventions
First Posted Date
2010-04-29
Last Posted Date
2014-09-15
Lead Sponsor
Children's National Research Institute
Target Recruit Count
7
Registration Number
NCT01113385
Locations
πŸ‡ΊπŸ‡Έ

Children's National Medical Center, Washington DC, District of Columbia, United States

Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor

Phase 1
Terminated
Conditions
Focal Segmental Glomerulosclerosis
Interventions
First Posted Date
2009-01-01
Last Posted Date
2015-09-10
Lead Sponsor
Northwell Health
Target Recruit Count
15
Registration Number
NCT00816478

Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5

Phase 1
Withdrawn
Conditions
Focal Segmental Glomerulosclerosis
Interventions
First Posted Date
2009-01-01
Last Posted Date
2015-09-07
Lead Sponsor
Northwell Health
Registration Number
NCT00816504
Locations
πŸ‡ΊπŸ‡Έ

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Phase 2
Completed
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Drug: Lisinopril, losartan, and atorvastatin
First Posted Date
2008-12-24
Last Posted Date
2016-07-11
Lead Sponsor
NYU Langone Health
Target Recruit Count
32
Registration Number
NCT00814255
Locations
πŸ‡ΊπŸ‡Έ

University of Michigan, Ann Arbor, Michigan, United States

πŸ‡ΊπŸ‡Έ

Children's Mercy Hospital, Kansas City, Missouri, United States

πŸ‡ΊπŸ‡Έ

Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States

and more 15 locations
Β© Copyright 2025. All Rights Reserved by MedPath